Dyne Therapeutics Inc

Company Profile

Dyne Therapeutics Inc had its IPO on 2020-09-17 under the ticker symbol DYN.

The company operates in the Healthcare sector and Biotechnology industry. Dyne Therapeutics Inc has a staff strength of 122 employees.

Stock update

Shares of Dyne Therapeutics Inc opened at $11.14 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $9.9 - $11.41, and closed at $9.9.

This is a -11.45% slip from the previous day's closing price.

A total volume of 894,569 shares were traded at the close of the day’s session.

In the last one week, shares of Dyne Therapeutics Inc have slipped by -15.89%.

Dyne Therapeutics Inc's Key Ratios

Dyne Therapeutics Inc has a market cap of $812.27 million, indicating a price to book ratio of 2.2375 and a price to sales ratio of 0.

In the last 12-months Dyne Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-178972992. The EBITDA ratio measures Dyne Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Dyne Therapeutics Inc’s operating margin was 0% while its return on assets stood at -33.38% with a return of equity of -61.1%.

In Q1, Dyne Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Dyne Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0.19

Its diluted EPS in the last 12-months stands at $-3.53 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.19. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Dyne Therapeutics Inc’s profitability.

Dyne Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.8947. Its price to sales ratio in the trailing 12-months stood at 0.

Dyne Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$288.64 million

Total Liabilities

$21.59 million

Operating Cash Flow

$0

Capital Expenditure

$230000

Dividend Payout Ratio

0%

Dyne Therapeutics Inc ended 2024 with $288.64 million in total assets and $0 in total liabilities. Its intangible assets were valued at $288.64 million while shareholder equity stood at $241.94 million.

Dyne Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $21.59 million in other current liabilities, 6000.00 in common stock, $-440760000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $181.11 million and cash and short-term investments were $238.21 million. The company’s total short-term debt was $4,644,000 while long-term debt stood at $0.

Dyne Therapeutics Inc’s total current assets stands at $238.21 million while long-term investments were $0 and short-term investments were $57.10 million. Its net receivables were $0 compared to accounts payable of $8.77 million and inventory worth $0.

In 2024, Dyne Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $230000.

Comparatively, Dyne Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$9.9

52-Week High

$15.63

52-Week Low

$4.75

Analyst Target Price

$30.57

Dyne Therapeutics Inc stock is currently trading at $9.9 per share. It touched a 52-week high of $15.63 and a 52-week low of $15.63. Analysts tracking the stock have a 12-month average target price of $30.57.

Its 50-day moving average was $11.19 and 200-day moving average was $12.03 The short ratio stood at 12.01 indicating a short percent outstanding of 0%.

Around 167.1% of the company’s stock are held by insiders while 9751.3% are held by institutions.